The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

An Autolus Therapeutics cell therapy has won FDA approval for treating an aggressive blood cancer. It’s the biotech’s first approved product and just the second CAR T-treatment for adults who have ...

Epic Systems and several healthcare providers have sued Health Gorilla and other companies, alleging they exploited ...

AI rivals Anthropic and OpenAI are both expanding their large language models into healthcare. Anthropic is blending its enterprise and consumer tools in a single platform, while OpenAI is separating ...

Physicians in the U.S. are doing more work than ever before — but they’re getting paid less. This month, consulting firm Kaufman Hall released new research on work relative value units, or wRVUs, for ...

In the past decade or two, health systems have been establishing their own venture capital arms to support health tech startups. At least 23 health systems currently have venture capital arms — mainly ...

Even when a drug finishes its production in the U.S., its active and inactive components often come from overseas. While pharmaceutical companies have been unveiling plans for new U.S. manufacturing ...

Banner Health — an Arizona-based health system with 30 hospitals and hundreds of other care sites — announced this week that it is deploying Qventus’ perioperative technology across the entire ...

Teladoc Health, a virtual care provider, has expanded its 24/7 urgent care service to treat more conditions, the company announced on Monday during the J.P. Morgan Healthcare Conference in San ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

The issue of waste in healthcare is garnering more attention than ever right now, and for good reason. Two bullet points illustrate the scope of our industry’s challenges: Let’s imagine, though, that ...